New combination tablet for type II diabetes

Qtern contains a fixed-dose combination of saxagliptin and dapagliflozin for use in type II diabetes inadequately controlled by metformin and/or a sulfonylurea plus saxagliptin or dapagliflozin.

The recommended dose of the saxagliptin/dapagliflozin (5mg/10mg) fixed-dose combination is 1 tablet daily.  | SCIENCE PHOTO LIBRARY
The recommended dose of the saxagliptin/dapagliflozin (5mg/10mg) fixed-dose combination is 1 tablet daily. | SCIENCE PHOTO LIBRARY

The film-coated tablets contain 5mg saxagliptin, a dipeptidyl peptidase 4 inhibitor, plus 10mg dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Qtern is also licensed for use in patients already being treated with the free combination of the components.

Clinical studies

The safety and efficacy of the saxagliptin/dapagliflozin fixed-dose combination was evaluated in three phase III studies involving 1,169 adults with type II diabetes.

In a 24-week trial (n=534) patients with type II diabetes inadequately controlled on metformin monotherapy were randomised to receive add-on therapy with saxagliptin/dapagliflozin (5mg/10mg, n=179), saxagliptin 5mg (n=176) or dapagliflozin 10mg (n=179).

Patients receiving add-on therapy with the saxagliptin/dapagliflozin combination achieved significantly greater reductions in HbA1c from baseline to week 24 than those receiving saxagliptin or dapagliflozin (-1.47% versus -0.88% [p<0.0001] and -1.20% [p=0.0166], respectively).

In another 24-week study involving 320 patients inadequately controlled on saxagliptin 5mg plus metformin the addition of dapagliflozin 10mg to therapy was associated with a significantly greater reduction in HbA1c at week 24 than the addition of placebo (p<0.0001). The effect on HbA1c observed at week 24 was sustained at week 52.

Similarly, in a 24-week trial involving 315 patients inadequately controlled on dapagliflozin 10mg plus metformin, patients who received add-on therapy with saxagliptin 5mg achieved significantly greater reductions in HbA1c at week 24 than those who received placebo (p<0.0001), an effect that was sustained at week 52.

Safety

The safety profile of the saxagliptin/dapagliflozin combination in these clinical studies for up to 52 weeks was comparable to those of the individual components.


Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.